Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Papers
(The TQCC of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis67
The human gut microbiota in people with amyotrophic lateral sclerosis52
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS42
Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study42
Focus on the heterogeneity of amyotrophic lateral sclerosis33
Telemedicine is a useful tool to deliver care to patients with Amyotrophic Lateral Sclerosis during COVID-19 pandemic: results from Southern Italy31
An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials30
Gut microbiome differences between amyotrophic lateral sclerosis patients and spouse controls30
Understanding the needs of people with ALS: a national survey of patients and caregivers28
Progression and survival of patients with motor neuron disease relative to their fecal microbiota28
Blended psychosocial support for partners of patients with ALS and PMA: results of a randomized controlled trial26
Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 201723
Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience23
TDP-43 pathology in primary lateral sclerosis20
Prevalence of amyotrophic lateral sclerosis (ALS), United States, 201620
Neuroimaging in primary lateral sclerosis20
The involvement of regulatory T cells in amyotrophic lateral sclerosis and their therapeutic potential20
Incidence of amyotrophic lateral sclerosis in the United States, 2014–201619
Grief, depression, and anxiety in bereaved caregivers of people with motor neurone disease: a population-based national study18
TRICALS: creating a highway toward a cure17
Prevalence of pain in amyotrophic lateral sclerosis: a systematic review and meta-analysis17
A multi-center study of neurofilament assay reliability and inter-laboratory variability16
Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R358Ala variant groups in amyotrophic lateral sclerosis patients16
Disorders of sleep and wakefulness in amyotrophic lateral sclerosis (ALS): a systematic review16
Amyotrophic lateral sclerosis caregiver burden and patients’ quality of life during COVID-19 pandemic15
Who cares for the bereaved? A national survey of family caregivers of people with motor neurone disease15
Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study15
Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches15
Differentiating needs of informal caregivers of individuals with ALS across the caregiving course: a systematic review15
Psychological interventions for people with motor neuron disease: a scoping review14
Associations between autoimmune diseases and amyotrophic lateral sclerosis: a register-based study14
Trauma and amyotrophic lateral sclerosis: a systematic review and meta-analysis13
A prospective study on split-hand index as a biomarker for the diagnosis of amyotrophic lateral sclerosis13
Genetics of primary lateral sclerosis13
Increased synthesis of pro-inflammatory cytokines in C9ORF72 patients13
The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis13
Pulmonary function decline in amyotrophic lateral sclerosis13
An online non-meditative mindfulness intervention for people with ALS and their caregivers: a randomized controlled trial12
The clinical spectrum of primary lateral sclerosis12
Apathy in amyotrophic lateral sclerosis: systematic review and meta-analysis of frequency, correlates, and outcomes12
Simultaneous ALS and SCA2 associated with an intermediate-length ATXN2 CAG-repeat expansion12
Muscle MRI in motor neuron diseases: a systematic review12
Cognitive reserve is associated with altered clinical expression in amyotrophic lateral sclerosis12
Estimation of forced vital capacity using speech acoustics in patients with ALS12
Neurophysiological features of primary lateral sclerosis11
Increased worsening of amyotrophic lateral sclerosis patients during Covid-19-related lockdown in France11
Motor Neuron Disease Register for England, Wales and Northern Ireland—an analysis of incidence in England11
Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis11
Natural history and clinical features of ALS in Malaysia11
Genetics of frontotemporal dementia in China11
Dyslipidemia in patients with amyotrophic lateral sclerosis – a case control retrospective study10
Case-control study in ALS using the National ALS Registry: lead and agricultural chemicals are potential risk factors10
The reading the mind in the eyes test short form (A & B): validation and outcomes in an amyotrophic lateral sclerosis cohort10
Epidemiological and genetic features of amyotrophic lateral sclerosis in Latin America and the Caribbean: a systematic review10
Percutaneous gastrostomy in amyotrophic lateral sclerosis: a review10
Human endogenous retrovirus K (HERV-K) env in neuronal extracellular vesicles: a new biomarker of motor neuron disease10
Resting state functional MRI brain signatures of fast disease progression in amyotrophic lateral sclerosis: a retrospective study10
The diagnostic value of the Italian version of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS)10
Novel serum autoantibodies against ß-actin (ACTB) in amyotrophic lateral sclerosis10
Patient reported outcomes in ALS: characteristics of the self-entry ALS Functional Rating Scale-revised and the Activities-specific Balance Confidence Scale10
Italian adaptation of the Beaumont Behavioral Inventory (BBI): psychometric properties and clinical usability10
Urinary p75ECD levels in patients with amyotrophic lateral sclerosis: a meta-analysis10
A de novo c.1509dupA:p.R503fs mutation of FUS: report of a girl with sporadic juvenile amyotrophic lateral sclerosis9
Novel FUS mutation Y526F causing rapidly progressive familial amyotrophic lateral sclerosis9
Genetic testing for amyotrophic lateral sclerosis in Canada – an assessment of current practices9
Neuropathology of primary lateral sclerosis9
Three different short-interval intracortical inhibition methods in early diagnosis of amyotrophic lateral sclerosis9
Levels of clusterin, CD5L, ficolin-3, and gelsolin in ALS patients and controls9
MRI biomarkers for memory-related impairment in amyotrophic lateral sclerosis: a systematic review8
Arterial blood gas analysis: base excess and carbonate are predictive of noninvasive ventilation adaptation and survival in amyotrophic lateral sclerosis8
Clinical characteristics in young-adult ALS – results from a Portuguese cohort study8
Mutations of DNAJC7 are rare in Chinese amyotrophic lateral sclerosis patients8
Neurofilament light chain as a biological marker for amyotrophic lateral sclerosis: a meta-analysis study8
Persian adaptation of Edinburgh Cognitive and Behavioural Screen (ECAS)8
Genotype-phenotype correlations of KIF5A stalk domain variants8
The epidemiology of amyotrophic lateral sclerosis in Moscow (Russia)8
Incidence of amyotrophic lateral sclerosis in Sardinia, Italy: age–sex interaction and spatial–temporal variability8
The path to diagnosis in ALS: delay, referrals, alternate diagnoses, and clinical progression8
Gastrointestinal biopsies and amyotrophic lateral sclerosis – results from a cohort study of 1.1 million individuals8
Juvenile amyotrophic lateral sclerosis with complex phenotypes associated with novel SYNE1 mutations8
History of vigorous leisure-time physical activity and early onset amyotrophic lateral sclerosis (ALS), data from the national ALS registry: 2010–20188
Cardiac troponin T is elevated and increases longitudinally in ALS patients8
Elevated plasma levels of D-serine in some patients with amyotrophic lateral sclerosis8
Respiratory onset in amyotrophic lateral sclerosis: clinical features and spreading pattern7
Analysis of incidence of motor neuron disease in England 1998–2019: use of three linked datasets7
Arabic adaptation and validation of the revised amyotrophic lateral sclerosis functional rating scale (ALSFRS-R): Egyptian study7
Clinical features and incidence trends of amyotrophic lateral sclerosis in Navarre, Spain, 2007–2018: a population-based study7
Validation of the Italian version of self-administered ALSFRS-R scale7
The Edinburgh Cognitive and Behavioral ALS Screen (ECAS) in frontotemporal dementia7
Mouth occlusion pressure at 100ms (P0.1) as a respiratory biomarker in amyotrophic lateral sclerosis7
Motor neuron disease beginning with frontotemporal dementia: clinical features and progression7
Reliable change indices for the Italian Edinburgh Cognitive and Behavioral ALS Screen (ECAS)7
ALSUntangled #64: butyrates7
Cerebellar degeneration in primary lateral sclerosis: an under-recognized facet of PLS7
The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) for Japanese ALS and FTD patients7
Dysfunction of the left angular gyrus may be associated with writing errors in ALS7
Problem-focused coping underlying lower caregiver burden in ALS-FTD: implications for caregiver intervention7
Juvenile amyotrophic lateral sclerosis associated with biallelic c.757delG mutation of sorbitol dehydrogenase gene6
What is amyotrophic lateral sclerosis prevalence?6
Tracheostomy ventilation in motor neurone disease: a snapshot of UK practice6
Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic6
The future of ALS diagnosis and staging: where do we go from here?6
Amyotrophic lateral sclerosis in the Faroe Islands – a genealogical study6
Comparison of the ability of the King’s and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis6
Impact of the covid-19 pandemic on amyotrophic lateral sclerosis care in the UK6
Clinical care and therapeutic trials in PLS6
Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures6
Characteristics of pain and the burden it causes in patients with amyotrophic lateral sclerosis – a longitudinal study6
Factors associated with Noninvasive ventilation compliance in patients with ALS/MND6
0.025314092636108